These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37368100)

  • 21. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
    Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2023 Aug; 33(8):1208-1214. PubMed ID: 37380217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
    Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
    Voronova V; Cullberg M; Delff P; Parkinson J; Dota C; Schiavon G; Maroj B; Rekić D; Cheung SYA
    Br J Clin Pharmacol; 2022 Feb; 88(2):858-864. PubMed ID: 34309049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
    Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
    Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial.
    Gatz SA; Harttrampf AC; Brard C; Bautista F; André N; Abbou S; Rubino J; Rondof W; Deloger M; Rübsam M; Marshall LV; Hübschmann D; Nebchi S; Aerts I; Thebaud E; De Carli E; Defachelles AS; Paoletti X; Godin R; Miah K; Mortimer PGS; Vassal G; Geoerger B
    Clin Cancer Res; 2024 Feb; 30(4):741-753. PubMed ID: 38051741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
    Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
    Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers.
    Noda N; Takagaki T; Yodo Y; Horibuchi Y; Iino S; Matsuki S; Ogama Y; Kakuyama H
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00874. PubMed ID: 34628720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
    Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
    Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E; Rathmell WK; Shapiro GI; Takebe N; Rodon J; Mahalingam D; Trikalinos NA; Kalebasty AR; Parikh M; Boerner SA; Balido C; Krings G; Burns TF; Bergsland EK; Munster PN; Ashworth A; LoRusso P; Aggarwal RR
    Cancer Res Commun; 2024 Jul; 4(7):1793-1801. PubMed ID: 38920407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
    Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
    Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors.
    Zhou X; Diderichsen PM; Gupta N
    Clin Pharmacol Drug Dev; 2022 Jun; 11(6):770-779. PubMed ID: 35187855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
    J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.